COVID-19 Vaccine Licensing Public Health 
Bill of Health
JANUARY 12, 2023
Moderna also licensed their mRNA technology from Cellscript LLC – University of Pennsylvania’s successor-in-interest to the 966 patent. Indeed, as made public, the U.S. government committed more than one billion dollars to Moderna for development of its COVID-19 vaccines.
Bill of Health
AUGUST 29, 2022
Legally speaking, patent pledges are comparable to the open source software licenses that underlie much of the world’s technology infrastructure and the Creative Commons licenses that make billions of online images, videos and other content freely available (both discussed here ). Tesla and Toyota) to software (e.g,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
JANUARY 6, 2022
The National Institutes of Health (NIH) is currently embroiled in a dispute over the ownership of patent rights to Moderna’s flagship mRNA COVID-19 vaccine (mRNA-1273). Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology.
Bill of Health
APRIL 6, 2022
It only narrowly modifies compulsory licenses of patents covering COVID vaccines. Moreover, it imposes additional restrictions on use of compulsory licenses. Moreover, Brazil’s new compulsory license law models another critical feature that domestic laws should have – a way around data exclusivity. Third, the U.S.
Bill of Health
APRIL 7, 2023
By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government substantially de-risking the vaccine development process.
Bill of Health
MARCH 24, 2022
Research funding contracts can help to safeguard against profound inequities in global allocation and distribution of lifesaving diagnostics, drugs, and vaccines. During large transnational public health crises, global demand soars for diagnostics, drugs, and vaccines. Using Contracts to Further Equity Goals.
Bill of Health
OCTOBER 31, 2022
Some COVID-19 vaccine manufacturers in the US have refused to share vaccine samples for research purposes , creating an access issue with the potential to delay comparator studies, follow-on research, and new vaccine / drug development. By Aparajita Lath.
Expert insights. Personalized for you.
318 
Let's personalize your content